Initial Treatment for HIV-1 Infection: how todays first-line care starts, succeeds, and evolves
💊 Starting HIV treatment is the first decision. Keeping it working for decades is a series of smaller ones: what a slightly raised viral load result means, whether it is worth moving from three tablets to one, what to do when a new medicine interacts, and how doctors tell a harmless blip from a regimen that is failing. 🎯 Modern regimens are so effective that most people stay undetectable for years on the same treatment, but almost everyone on lifelong therapy will change something at some point. This guide explains the viral load thresholds that matter, the common reasons to switch, the rules that make a switch safe, what happens when treatment fails, and how drug resistance is tested and handled.
📖 If you are about to start treatment for the first time, begin with starting HIV treatment: the first regimen and the first year. This article picks up from there.
🎯 The goal that every decision serves
🛡️ An undetectable viral load protects the immune system, lets the CD4 count recover, and means HIV is not passed on through sex. It also protects the regimen itself: a virus that is not copying cannot mutate, so resistance almost never develops while the viral load stays suppressed.
📏 Reading a viral load result
🧪 Viral load is the number of copies of HIV genetic material per millilitre of blood. Modern tests detect down to 20 to 50 copies. The number on its own matters less than which band it falls in, and whether it is repeated.
undetectable
blip or low-level
low-level viraemia
likely failure
📉 How fast the viral load falls after starting
📅 How often viral load is checked
| 📅 Stage | 🧪 Viral load test |
|---|---|
| After starting or switching | At 4 to 8 weeks, then every 4 to 8 weeks until below 50 |
| First 1 to 2 years undetectable | Every 3 to 4 months |
| Stable for 2 years or more | Every 6 months, sometimes yearly in some programmes |
| After a detectable result | Repeat within 2 to 6 weeks, after an adherence check |
| Pregnancy | More often, including near delivery |
📈 What a viral blip is
🔎 A blip is a single detectable result, usually between 50 and 199 copies, with results below 50 before and after it. Blips are common; in long-term studies around a quarter to a third of people on suppressive treatment have at least one. They reflect normal test variation, a recent infection or vaccine that briefly activated the immune system, or virus released from long-lived resting cells. ✅ An isolated blip does not mean resistance and does not mean the regimen should change.
🟡 Low-level viraemia: the grey zone
⚖️ Repeated results between 50 and 200, or between 200 and 1,000, are called low-level viraemia. Persistent results above 200 carry a real risk of resistance building over time, and studies link persistent levels above 200 to later failure. Doctors usually respond by checking adherence and interactions, repeating the test, and, if it persists above 200, ordering resistance testing and considering a change.
🚦 What happens after a detectable result
🧬 Drug resistance: how it develops
🔁 HIV copies itself billions of times a day with frequent errors. When drug levels are too low to stop copying completely, because of missed doses, poor absorption or an interaction, variants that are slightly less sensitive get an advantage and take over. Resistance is therefore a consequence of ongoing copying in the presence of the drug, not of the drug itself.
🛡️ Drugs differ in how easily this happens. This is called the genetic barrier to resistance: how many mutations the virus needs before the drug stops working.
| 💊 Drug or class | 🛡️ Barrier | 📝 What that means |
|---|---|---|
| Dolutegravir, bictegravir | High | Resistance is rare in first-line use, even after adherence problems |
| Boosted darunavir | High | Often used after failure for this reason |
| Lamivudine, emtricitabine | Low | One mutation, M184V, causes high-level resistance |
| Tenofovir | Medium | Mutation K65R; tenofovir often still partly active after failure |
| Efavirenz, nevirapine | Very low | A single mutation, K103N, can make the whole class useless |
| Raltegravir, elvitegravir | Low to medium | Older integrase inhibitors; mutations may affect later options |
🧪 Resistance testing in practice.
🔹 Standard genotype tests need a viral load above about 500 to 1,000 copies; some labs can test from 200.
🔹 Take the sample while still on the failing regimen, or within 4 weeks of stopping; resistant virus fades from the blood when the drug is gone, but stays archived in cells.
🔹 Integrase resistance may need a separate request, as it is not always in the standard panel.
🔹 When the viral load is undetectable, a proviral DNA test can look at archived resistance before a switch.
❌ Treatment failure: what it is and is not
📋 Virological failure means the regimen is not keeping the virus below 200 copies on repeat testing. In most cases today, the cause is that the tablets are not being absorbed every day, not that the virus has become resistant. 💊 With dolutegravir-based treatment, many people who fail because of missed doses re-suppress on the same regimen once dosing is back on track, because the drug has not lost activity.
- 📅 Missed doses: the leading cause by far. Work, travel, mood, stigma at home, cost and side effects all play a part
- 🍽️ Absorption: antacids, iron, calcium and magnesium taken at the same time as dolutegravir
- 🔗 Interactions: rifampicin, some anticonvulsants, St John’s wort lower drug levels
- 🧬 Resistance: transmitted at infection or developed during earlier treatment, especially with efavirenz or nevirapine
- 🤢 Vomiting or diarrhoea for days, which lowers absorption
🔄 Switching a regimen that is working
💡 Most switches happen while the viral load is undetectable, for reasons of comfort, safety or convenience. This is called a switch for optimisation, and it is very different from a switch for failure.
📋 Common reasons to switch
| 📋 Reason | 🔄 Typical change |
|---|---|
| 🌙 Sleep problems, vivid dreams, low mood | From efavirenz, such as Sustiva (Efavirenz), to a dolutegravir-based regimen |
| 💊 Many tablets a day | To one tablet once daily, such as Viropil (Dolutegravir + Lamivudine + Tenofovir) |
| 🫘 Kidney function falling, bone thinning | From tenofovir disoproxil to tenofovir alafenamide, or a tenofovir-free regimen |
| 🩸 Anaemia, fat loss in face and limbs | Away from zidovudine or stavudine, which are no longer recommended for routine use |
| 🔗 A new medicine with interactions | Away from boosted regimens, for example before statins, some heart drugs or inhaled steroids |
| ❤️ High cholesterol or heart risk | To a regimen with a better lipid profile |
| 🤱 Planning pregnancy | To a regimen with good pregnancy data, usually dolutegravir-based |
📜 The safety rules for any switch
✌️ Two-drug regimens
💊 Dolutegravir with lamivudine, as two drugs instead of three, keeps the viral load suppressed as well as three-drug regimens in large switch trials, in people who were already undetectable. It suits people without hepatitis B and without lamivudine resistance, and avoids tenofovir’s kidney and bone effects. Dolutegravir can be combined with Epivir (Lamivudine) as two tablets when a fixed combination is not available.
| ✌️ Two drugs | 📝 Detail |
|---|---|
| ✅ Fewer drugs | No tenofovir; less effect on kidneys and bones |
| ✅ Same suppression | In switch trials, equal to three drugs over several years |
| ❌ Not with hepatitis B | Lamivudine alone is not enough for hepatitis B and leads to resistance |
| ❌ Less forgiving if resistance exists | Past M184V or integrase mutations rule it out in most cases |
💉 Long-acting injections
📅 For people who are already undetectable and have no resistance to the two drugs, cabotegravir with rilpivirine given as injections every one or two months replaces daily tablets. It suits people who struggle with daily pills or the privacy of tablets at home. The injections must be given on schedule in a clinic, and late injections can let resistance develop to both drugs, so it is not a choice for anyone who misses appointments.
💊 Dolutegravir: details that matter in daily life
💊 Xapavir (Dolutegravir 50 mg) is the anchor of most current regimens, alone with other drugs or inside a combination tablet. It is once daily, with or without food, and stays in the blood long enough that one late dose is not a crisis.
🌙 The most common side effects are trouble sleeping and headache, usually mild and easing over weeks; taking the tablet in the morning can help sleep. Some people gain weight on integrase inhibitors, especially when switching from efavirenz or tenofovir disoproxil, so weight is tracked at each visit.
🤱 Dolutegravir in pregnancy
📊 An early signal in 2018 suggested a higher rate of neural tube defects with dolutegravir at conception. Larger follow-up data showed the difference was very small and not significant, about 1 in 1,000 births, close to other regimens. Dolutegravir-based treatment is now a preferred option before and during pregnancy, and folic acid is advised as for any pregnancy.
⏰ Missed doses
- ⏰ Remembered within about 12 hours on a once-daily regimen: take it now, then the next one at the usual time
- 📅 Close to the next dose: skip the missed one; never take two at once
- 🤢 Vomited within an hour of the dose: take another
- 💬 Several missed doses in a row: restart and tell the clinic; a viral load check may follow
🩺 Emily Chen, MD, MPH, on a raised result
When a viral load comes back detectable, the first reaction is often fear that the treatment has failed for good. With today’s regimens, that is rarely the case. I start with an open conversation about the last month: a new job with night shifts, a stomach bug, iron tablets started for anaemia, a hard stretch at home. Most of the time we find the cause, fix it, and the repeat test is back below 50. Being honest with the clinic about missed doses is the fastest way to protect your options.
🔥 After failure: building the next regimen
🧩 When resistance is confirmed, the new regimen is built from the test result and the full history. The aim is at least two, and ideally three, drugs that are fully active against the virus. After first-line failure on an efavirenz-based regimen, a dolutegravir-based regimen often works well, even when tenofovir and lamivudine have reduced activity, because dolutegravir carries so much of the load. After failure with integrase resistance, boosted darunavir and newer agents are typically involved, with a specialist leading the choice.
⛔ What not to do.
🔹 Do not stop all treatment because of a detectable result; the viral load will rise much further.
🔹 Do not add one new drug to a failing regimen; the virus becomes resistant to it too.
🔹 Do not switch before the resistance sample is taken.
🔹 Do not take treatment breaks; planned interruptions raised illness and death rates in trials.
📋 Older drugs still on the market
| 💊 Medicine | 📝 Where it fits today |
|---|---|
| Sustiva (Efavirenz) | Still effective; no longer first choice because of sleep and mood effects and its low resistance barrier |
| Combivir (Lamivudine + Zidovudine) | Used in specific situations; anaemia needs blood count checks |
| Retrovir (Zidovudine) | Still used in newborn prevention and some second-line regimens |
| Stavudine | Phased out of routine use because of nerve damage, fat loss and lactic acidosis |
❤️ Long-term health on any regimen
📅 People who stay undetectable now have a life expectancy close to the general population. The main long-term risks are heart disease, kidney disease, bone thinning and some cancers, partly from ageing and lifestyle and partly from low-level inflammation. Not smoking, blood pressure and cholesterol control, cervical and anal screening where advised, and vaccinations matter as much as the tablets after the first years.
🗿 Beliefs that cause problems
| 💭 The belief | ✔️ What is actually the case |
|---|---|
| “Any detectable result means my treatment failed.” | A single low result is usually a blip. The repeat test decides |
| “If I am undetectable I can take breaks.” | The virus returns within weeks of stopping. Breaks raise illness risk |
| “Switching means my regimen was not good.” | Most switches are planned improvements while undetectable |
| “Resistance goes away once I stop that drug.” | It hides in cells for life and returns if the drug is used again |
| “Telling the clinic about missed doses will get me in trouble.” | It is the information that protects your options |
🚨 When to contact the clinic, and how fast
❓ Frequently asked questions
What is a standard HIV-1 treatment regimen today?
Usually an integrase inhibitor such as dolutegravir or bictegravir with two other drugs, often in one daily tablet. Some people use dolutegravir with lamivudine alone.
What is a viral blip?
A single detectable result, usually 50 to 199 copies, with undetectable results before and after. It does not mean failure or resistance.
What viral load counts as treatment failure?
A viral load of 200 copies/mL or more confirmed on a repeat test. Some programmes use 1,000 copies as the threshold.
Can I switch HIV medication if I am undetectable?
Yes, switches for fewer tablets or side effects are common, after a review of past regimens, resistance results and hepatitis B status.
How soon is viral load checked after a switch?
Usually 4 to 8 weeks after the switch, then at the normal schedule if it stays below 50.
How does HIV drug resistance develop?
When drug levels are too low to stop the virus copying, often from missed doses or interactions, resistant variants are selected and take over.
Is a two-drug regimen as good as three drugs?
Dolutegravir with lamivudine keeps suppression as well as three drugs in suitable people, but not with hepatitis B or lamivudine resistance.
Can I take antacids or iron with dolutegravir?
Take dolutegravir 2 hours before or 6 hours after them, or take calcium or iron together with dolutegravir and a meal.
What should I do if I miss a dose?
On a once-daily regimen, take it within about 12 hours; if the next dose is close, skip it. Never double up.
Is dolutegravir safe in pregnancy?
Yes. Large data showed no meaningful rise in birth defects, and dolutegravir-based regimens are a preferred option before and during pregnancy.
📑 Sources and editorial
- 📘 National and international guidelines on antiretroviral therapy in adults, including WHO consolidated HIV guidelines
- 📊 Randomised trials of integrase-based first-line regimens with 48-week and longer outcomes
- 📈 Cohort studies of viral blips and low-level viraemia and their link to later failure
- 🧬 Reviews of HIV drug resistance mutations and genetic barriers by drug class
- ✌️ Switch trials of dolutegravir with lamivudine in people with suppressed viral load
- 💉 Trials of long-acting cabotegravir and rilpivirine injections
- 🤱 Birth outcome surveillance data on dolutegravir at conception
- ⏸️ Randomised trials of planned treatment interruption
- 📖 Related reading: starting HIV treatment: the first regimen and the first year
- 🛒 Related products: Xapavir (Dolutegravir), Viropil (Dolutegravir + Lamivudine + Tenofovir), Epivir (Lamivudine), Sustiva (Efavirenz), Combivir (Lamivudine + Zidovudine)
- 🩺 RXshop Editorial Team — reviewed by Emily Chen, MD, MPH — Internal Medicine
Medical Disclaimer: The information in this article is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek guidance from a qualified healthcare provider with any questions you may have regarding a medical condition, and before starting, stopping or changing any medication.